Sarah Melville
@sarahkmels.bsky.social
More IgAN information this Monday via the @csnscn.bsky.social webinar: www.csncommunity.ca?fbclid=IwdGR...
(free to register), 🤓😃🙏
#nephjc
(free to register), 🤓😃🙏
#nephjc
CSN/SCN COMMUNITY - Registration
www.csncommunity.ca
November 19, 2025 at 3:59 AM
More IgAN information this Monday via the @csnscn.bsky.social webinar: www.csncommunity.ca?fbclid=IwdGR...
(free to register), 🤓😃🙏
#nephjc
(free to register), 🤓😃🙏
#nephjc
Reposted by Sarah Melville
Yes! It can be hard but most folks don't get a lot of symptoms on 0.25 dose. If they go to 0.5 and have issues, go back to 0.25 and go up by "clicks" instead of full dose! See: diabetesjournals.org/care/article...
One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens
Glucagon-like peptide 1 receptor agonists (GLP-1RA) have transformed the landscape of type 2 diabetes and chronic weight management (1). Clinical trials ha
diabetesjournals.org
March 6, 2025 at 12:30 PM
Yes! It can be hard but most folks don't get a lot of symptoms on 0.25 dose. If they go to 0.5 and have issues, go back to 0.25 and go up by "clicks" instead of full dose! See: diabetesjournals.org/care/article...
Reposted by Sarah Melville
I love this tradition #NephJC
a man in a suit and tie is saying stay classy .
ALT: a man in a suit and tie is saying stay classy .
media.tenor.com
November 19, 2025 at 3:01 AM
I love this tradition #NephJC
Reposted by Sarah Melville
We likely will have to treat IgA patients differently based on their disease timeline. New, flaring patients need upstream treatment, chronic patients that have damage that can’t be unfibrosed need a different therapy plan. There are plenty of patients for all our therapy options. #nephjc
November 19, 2025 at 2:59 AM
We likely will have to treat IgA patients differently based on their disease timeline. New, flaring patients need upstream treatment, chronic patients that have damage that can’t be unfibrosed need a different therapy plan. There are plenty of patients for all our therapy options. #nephjc
Reposted by Sarah Melville
I think Aliza Thompson is an unsung hero in this story for spearheading the albuminuria acceptance at FDA
journals.lww.com/cjasn/pages/...
#NephJC
journals.lww.com/cjasn/pages/...
#NephJC
journals.lww.com
November 19, 2025 at 3:00 AM
I think Aliza Thompson is an unsung hero in this story for spearheading the albuminuria acceptance at FDA
journals.lww.com/cjasn/pages/...
#NephJC
journals.lww.com/cjasn/pages/...
#NephJC
Reposted by Sarah Melville
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
November 19, 2025 at 2:41 AM
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Reposted by Sarah Melville
T3g: #NephJC
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
November 19, 2025 at 2:42 AM
T3g: #NephJC
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
Reposted by Sarah Melville
T3j: #NephJC
Overall, these interim results suggest that APRIL-based and BAFF/APRIL–based therapies may represent important future disease-modifying options in IgAN
A full throated, “Hallelujah” being reserved until eGFR data is finalized.
Overall, these interim results suggest that APRIL-based and BAFF/APRIL–based therapies may represent important future disease-modifying options in IgAN
A full throated, “Hallelujah” being reserved until eGFR data is finalized.
November 19, 2025 at 2:45 AM
T3j: #NephJC
Overall, these interim results suggest that APRIL-based and BAFF/APRIL–based therapies may represent important future disease-modifying options in IgAN
A full throated, “Hallelujah” being reserved until eGFR data is finalized.
Overall, these interim results suggest that APRIL-based and BAFF/APRIL–based therapies may represent important future disease-modifying options in IgAN
A full throated, “Hallelujah” being reserved until eGFR data is finalized.
Reposted by Sarah Melville
Reposted by Sarah Melville
T3d: #NephJC
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
November 19, 2025 at 2:39 AM
T3d: #NephJC
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
Reposted by Sarah Melville
Reposted by Sarah Melville
Ongoing late posts from @theisn.org #ISNWCN
from the high impact trial session - this was a great study design
The India ALLIANCE GRACE IgAN trial
Lead by Succeena Alexander from CMC Vellore
#NephSky
1/
from the high impact trial session - this was a great study design
The India ALLIANCE GRACE IgAN trial
Lead by Succeena Alexander from CMC Vellore
#NephSky
1/
November 19, 2025 at 2:39 AM
Reposted by Sarah Melville
T0k: #NephJC
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:19 AM
T0k: #NephJC
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
Reposted by Sarah Melville
Reposted by Sarah Melville
These are not FDA approved yet - this trial + VISIONARY for Sibeprenlimab will lead to approval soon
Approved =
Nefecon
Atrasentan
Sparsentan
Iptacopan
(I think)
#Nephjc
Approved =
Nefecon
Atrasentan
Sparsentan
Iptacopan
(I think)
#Nephjc
November 19, 2025 at 2:20 AM
These are not FDA approved yet - this trial + VISIONARY for Sibeprenlimab will lead to approval soon
Approved =
Nefecon
Atrasentan
Sparsentan
Iptacopan
(I think)
#Nephjc
Approved =
Nefecon
Atrasentan
Sparsentan
Iptacopan
(I think)
#Nephjc
Reposted by Sarah Melville
T1a: #NephJC
ORIGIN 3 is a:
🌐 multinational
🎲 randomized
👀 double-blind
💉💉 placebo-controlled
3️⃣ phase 3 trial evaluating atacicept in IgA nephropathy
ORIGIN 3 is a:
🌐 multinational
🎲 randomized
👀 double-blind
💉💉 placebo-controlled
3️⃣ phase 3 trial evaluating atacicept in IgA nephropathy
November 19, 2025 at 2:21 AM
T1a: #NephJC
ORIGIN 3 is a:
🌐 multinational
🎲 randomized
👀 double-blind
💉💉 placebo-controlled
3️⃣ phase 3 trial evaluating atacicept in IgA nephropathy
ORIGIN 3 is a:
🌐 multinational
🎲 randomized
👀 double-blind
💉💉 placebo-controlled
3️⃣ phase 3 trial evaluating atacicept in IgA nephropathy
Reposted by Sarah Melville
T1b: #NephJC
👉The study consists of 4 defined periods
👉The double-blind treatment took place for 104 weeks
🔍The interim analysis included blinded data at 36 weeks, not the full 104-week dataset
👉The study consists of 4 defined periods
👉The double-blind treatment took place for 104 weeks
🔍The interim analysis included blinded data at 36 weeks, not the full 104-week dataset
November 19, 2025 at 2:22 AM
T1b: #NephJC
👉The study consists of 4 defined periods
👉The double-blind treatment took place for 104 weeks
🔍The interim analysis included blinded data at 36 weeks, not the full 104-week dataset
👉The study consists of 4 defined periods
👉The double-blind treatment took place for 104 weeks
🔍The interim analysis included blinded data at 36 weeks, not the full 104-week dataset
Reposted by Sarah Melville
T0h: #NephJC
Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation.
www.kidneynews.org/v...
Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation.
www.kidneynews.org/v...
November 19, 2025 at 2:15 AM
T0h: #NephJC
Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation.
www.kidneynews.org/v...
Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation.
www.kidneynews.org/v...
Reposted by Sarah Melville
Coming from a country where these meds aren’t even available yet, I have to admit... I’m a little envious on behalf of my patients #nephJC
November 19, 2025 at 2:07 AM
Coming from a country where these meds aren’t even available yet, I have to admit... I’m a little envious on behalf of my patients #nephJC
Reposted by Sarah Melville
Shouldn't there be a clause at the beginning of the trial? that they must make it available in countries where the trial participants were there? #NephJC
November 19, 2025 at 2:16 AM
Shouldn't there be a clause at the beginning of the trial? that they must make it available in countries where the trial participants were there? #NephJC
Reposted by Sarah Melville
Same here in 🇨🇦!
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Physical Accessibility of Medicines in Countries Hosting Trials for FDA Approvals
This cross-sectional study aims to determine whether and when medicines receive market authorization in the countries where they are tested for US Food and Drug Administration approval, as well as tre...
jamanetwork.com
November 19, 2025 at 2:12 AM
Same here in 🇨🇦!
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Reposted by Sarah Melville
Before we start, take a look at the article itself #NephJC
Does anyone see the authors?
Have you read the lovely, >500 pages of supplement? No problem @kidneyboy.bsky.social has volunteered to do it for all of us!
pubmed.ncbi.nlm.nih....
Does anyone see the authors?
Have you read the lovely, >500 pages of supplement? No problem @kidneyboy.bsky.social has volunteered to do it for all of us!
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:07 AM
Before we start, take a look at the article itself #NephJC
Does anyone see the authors?
Have you read the lovely, >500 pages of supplement? No problem @kidneyboy.bsky.social has volunteered to do it for all of us!
pubmed.ncbi.nlm.nih....
Does anyone see the authors?
Have you read the lovely, >500 pages of supplement? No problem @kidneyboy.bsky.social has volunteered to do it for all of us!
pubmed.ncbi.nlm.nih....